23:58 , Aug 15, 2019 |  BC Extra  |  Company News

Management tracks: New executives at Pfizer spinouts Cerevel and SpringWorks

Cerevel Therapeutics LLC (Boston, Mass.) hired Orly Mishan as CBO, a newly created role. She was principal and a founding member of Bain Capital Life Sciences, which launched the Pfizer Inc. (NYSE:PFE) spinout with $350...
00:51 , May 31, 2019 |  BC Innovations  |  Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
21:41 , May 29, 2019 |  BC Extra  |  Company News

May 29 Company Quick Takes: Priority Review for Amarin's Vascepa; plus Tuhura-Moffitt Cancer Center deal and more

Priority Review for Vascepa to reduce CV risk  Amarin Corp. plc (NASDAQ:AMRN) gained $1.98 (12%) to $18.99 on Wednesday after FDA accepted and granted Priority Review to an sNDA for Vascepa icosapent ethyl to reduce...
23:59 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer; colorectal cancer; lung cancer Cell culture and mouse studies suggest inhibiting GSK3 could help treat KRAS-driven pancreatic, colon and lung cancers. Screening of a library of 304 kinase inhibitors in cell-based growth...
20:05 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Aprea's MDS candidate leads to 95% ORR in Phase Ib/II

Aprea Therapeutics AB (Stockholm, Sweden) reported data from 20 evaluable patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) in a Phase Ib/II trial showing that APR-246 plus Vidaza azacitidine led to an overall...
19:46 , Nov 1, 2018 |  BC Innovations  |  Emerging Company Profile

Secarna’s next-gen oligos

Secarna Pharmaceuticals GmbH’s antisense oligonucleotides for immuno-oncology could have better tissue penetration than small molecules and antibodies against the same targets. The company was established in 2015 by the founders and investors who launched antisense...
19:32 , Sep 7, 2018 |  BC Week In Review  |  Company News

Atara partners with Moffitt Cancer Center to develop CAR T therapies

Atara Biotherapeutics Inc. (NASDAQ:ATRA) partnered with H. Lee Moffitt Cancer Center and Research Institute (Tampa, Fla.) to develop multi‑targeted CAR T immunotherapies to treat cancers with diverse cell types that often become resistant to treatment,...
19:49 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

Aprea reports Phase Ib/II response data for APR-246 in MDS

Aprea Therapeutics AB (Stockholm, Sweden) said APR-246 plus Vidaza azacitidine led to an overall response rate (ORR) of 100%, including six complete responses and two marrow complete responses, in eight evaluable patients with myelodysplastic syndrome...
22:47 , Mar 14, 2018 |  BC Extra  |  Politics & Policy

AACR launches African-American sequencing initiative

The American Association for Cancer Research is launching a genomics sequencing initiative called 2020 by 2020 to help study cancer outcomes in African-Americans. The initiative -- which includes The Ohio State University Comprehensive Cancer Center,...
19:52 , Jul 28, 2017 |  BC Week In Review  |  Company News

Helix, Moffitt explore data extraction and checkpoint inhibitors with L-DOS47

H. Lee Moffitt Cancer Center and Research Institute (Tampa, Fla.) and Helix BioPharma Corp (TSX:HBP) partnered in two separate deals concerning L-DOS47 from Helix. The first deal involves the extraction of radiomics data from CT...